The dark side of cyclophosphamide: Cyclophosphamide-mediated ablation of regulatory T cells

Journal of Investigative Dermatology

Volumn 133, Issue 6, 2013, Pages 1462-1465

  Becker, Jürgen C ^a   Schrama, David ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; B7 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; BONE MARROW CELL; CANCER GRAFT; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; EXPERIMENTAL MOUSE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; THERAPY EFFECT; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84878537855     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.67     Document Type: Note

References (20)

1. Angulo I, las Heras de FG, García-Bustos JF et al. (2000) Nitric oxide-producing CD11b+ Ly-6G Gr-1+ CD31+ cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95:212-20
2. Becker JC, Andersen MH, Hofmeister-Mü ller V et al. (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 61:2091-103
3. Diaz-Montero CM, Salem ML, Nishimura MI et al. (2008) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49-59
4. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-99
5. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-22
6. Iiai T, Watanabe H, Iwamoto T et al. (1994) Predominant activation of extrathymic T cells during melanoma development of metallothionein/ ret transgenic mice. Cell Immunol 153:412-27
7. Kerkar SP, Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72:3125-30
8. Kodumudi KN, Weber A, Sarnaik AA et al. (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189:5147-54
9. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439-44
10. Le HK, Graham L, Cha E et al. (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9:900-9
11. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-9
12. Meyer C, Sevko A, Ramacher M et al. (2011) Chronic inflammation promotes myeloidderived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108:17111-6
13. Poschke I, Kiessling R (2012) On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 144:250-68
14. Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
15. Sakaguchi S, Yamaguchi T, Nomura T et al. (2008) Regulatory T cells and immune tolerance. Cell 133:775-87
16. Sevko A, Sade-Feldman M, Kanterman J et al. (2013) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents anti-tumor response in melanoma. J Invest Dermatol 133:1610-9
17. Vincent J, Mignot G, Chalmin F et al. (2010) 5-Fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T cell-dependent anti-tumor immunity. Cancer Res 70:3052-61
18. Walter S, Weinschenk T, Stenzl A et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254-61
19. Wang E, Uccellini L, Marincola FM (2012) A genetic inference on cancer immune responsiveness. Oncoimmunology 1:520-5
20. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307